08:15 AM EDT, 06/09/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Monday it will return $375 million in excess capital to shareholders after completing a strategic review.

The company said its board evaluated multiple options, including a sale, a merger, continued pipeline investment, or capital return, with assistance from outside advisors.

The decision is based on its capital needs, shareholder input, and confidence in its lead candidate, KER-065, for Duchenne muscular dystrophy, Keros said.

Shares of the company were down by more than 5% in recent Monday premarket activity.

Price: 14.20, Change: -0.84, Percent Change: -5.59